Navigation Links
Luminex Corporation Launches New FDA Cleared Pharmacogenetic Diagnostic Test
Date:11/17/2010

AUSTIN, Texas, Nov. 17, 2010 /PRNewswire-FirstCall/ -- Luminex Corporation (Nasdaq: LMNX), today announced that it has commercially launched its first pharmacogenetic test, the xTAG® CYP2D6 Kit, which recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The new test enables a personalized medicine approach to help physicians manage patients for whom they may prescribe certain drugs that are metabolized by the enzyme cytochrome P450 2D6.

(Logo:  http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100104/LUMINEXLOGO)

"The xTAG CYP2D6 Kit will be an important tool in the fast-growing field of personalized medicine," said Patrick J. Balthrop, president and CEO of Luminex. "The first innovation in CYP2D6 diagnostics in five years, it combines the power of multiplexing with the promise of pharmacogenetics. The information it provides has significant potential to help doctors improve care by assisting them in determining the best therapeutic strategy for an individual patient."

CYP2D6 is an enzyme that is involved in the metabolism of approximately one quarter of all prescription drugs, including betablockers, opiates, selective serotonin reuptake inhibitors (SSRIs), tricylic antidepressants (TCAs), neuroleptics and antiarrhythmics. People may carry a slow- or fast–acting form of the enzyme while others have a non-functional version of the CYP2D6 gene, or allele, which can affect how an individual's body responds to these therapies.

The xTAG CYP2D6 Kit helps identify individuals who possess both common and rare CYP2D6 poor-metabolizer variants. Abnormal metabolizers are more likely to experience adverse drug reactions from medications acted upon by CYP2D6 and can be at increased risk of dangerous drug-induced side effects, drug interactions and therapeutic failure. These individuals may need to receive alternative treatment doses and undergo drug level monitoring.

"The clinical utility of CYP2D6 genotyping is very important and diverse, as the enzyme metabolizes nearly 25 percent of all medications used across a myriad of medical disciplines. Combined with 10 percent poor-metabolizer phenotype in the general population, it dictates a critical need for the availability of high quality CYP2D6 genotyping," said Kristen Reynolds, PhD, vice president of Laboratory Operations, PGXL Laboratories. "The xTAG CYP2D6 assay from Luminex provides our lab with a robust multiplex assay, which allows for higher throughput, shorter turnaround times, and less per-sample cost than previous CYP2D6 genotyping technologies."

The xTAG CYP2D6 Kit is the second test of its kind to be cleared by FDA. It is a qualitative genotyping assay that can simultaneously detect and identify a panel of single-nucleotide polymorphism (SNP) variants found within the CYP2D6 gene. It also identifies gene rearrangements associated with deletion and duplication genotypes.

The xTAG CYP2D6 assay features a simple laboratory workflow and provides accurate results in 8 hours. It is based on Luminex's flexible xMAP® Technology and is designed to be used on the widely distributed Luminex 200 system. It is uniquely suited for laboratories that offer cytochrome P450 drug metabolism testing services to physicians including psychiatrists, hospital pharmacologists, oncologists and general practitioners, who may treat patients with medical therapies that are metabolized all or in part by CYP2D6.

The first in a line of CYP products Luminex is developing; the xTAG CYP2D6 Kit is now commercially available from Luminex Molecular Diagnostics and its distribution partner, Fisher HealthCare.

The xTAG CYP2D6 Kit is not indicated for stand-alone diagnostic purposes and is not intended to be used to predict drug response or non-response.  

For more information, call 512.219.8020, or visit www.luminexcorp.com.

About Luminex CorporationLuminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company's xMAP technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP can be obtained at www.luminexcorp.com.Luminex Investor Contact:  Matt Scalo, Senior Director of Investor Relations  512.219.8020  mscalo@luminexcorp.com Luminex Media Contacts:  Mimi L. Torrington, Director of Marketing Communications 512.219.8020  mtorrington@luminexcorp.com Brandon Brunson512.241.2234Brandon.Brunson@porternovelli.com
'/>"/>

SOURCE Luminex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Luminex Corporation to Present at Stephens Fall Investment Conference
2. Luminex Corporation Reports Third Quarter 2010 Results
3. Luminex Corporation Third Quarter Earnings Release Scheduled for November 4, 2010
4. Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna
5. Tecan Group and Luminex Corporation Partner to Develop Automated Newborn Screening Solution
6. Luminex Corporation Wins Prestigious 2010 Prix Galien USA Award
7. Luminex to Host MAGPIX Road Shows Throughout the U.S. and Europe
8. Luminex Corporation to Present at UBS Global Life Sciences Conference
9. Luminex MAGPIX System Shown to be More Cost Effective and Efficient Than Conventional ELISA Method in Initial Study
10. Luminex Announces Commercial Launch of New Cystic Fibrosis Test
11. Luminex Donates Companys First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):